Abstract
Background
Methods
Results
ACKNOWLEDGMENTS
References
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Fig. 1
Associations between serum proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations and numbers of involved arteries identified by coronary angiography. NS, not significant. aP<0.05.
![dmj-42-207-g001](/upload/SynapseXML/2004dmj/thumb/dmj-42-207-g001.jpg)
Table 1
Baseline clinical characteristics of study participants with and without coronary angiographic lesions
![dmj-42-207-i001](/upload/SynapseXML/2004dmj/thumb/dmj-42-207-i001.jpg)
Values are presented as mean±standard deviation (which were compared by Student t-tests) or number (%) in each category (which were compared by chi-square tests).
IHD, ischemic heart disease; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal pro-B type natriuretic peptide; PCSK9, proprotein convertase subtilisin/kexin type 9.
aNo lesion, no coronary arterial lesion at coronary angiography, bLesion, one or more coronary arterial lesions at coronary angiography.
Table 2
Baseline clinical characteristics of study participants stratified into tertiles according to serum levels of PCSK9
![dmj-42-207-i002](/upload/SynapseXML/2004dmj/thumb/dmj-42-207-i002.jpg)
Values are presented as mean±standard deviation or number (%).
PCSK9, proprotein convertase subtilisin/kexin type 9; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal pro-B type natriuretic peptide; CAG, coronary angiography; SYNTAX, SYNergy between percutaneous coronary intervention with (paclitaxel-eluting) TAXUS stent and cardiac surgery; GRACE, Global Registry of Acute Coronary Events.
aP value of tertile 3 (highest PCSK9) compared with tertile 1 (lowest PCSK9), determined by Student t-tests for continuous variables or chi-square tests for categorical variables.
Table 3
Odds ratios for the presence of one or more coronary angiographic lesions in patients in different PCSK9 tertiles
![dmj-42-207-i003](/upload/SynapseXML/2004dmj/thumb/dmj-42-207-i003.jpg)
Odds ratios were calculated for the presence of one or more coronary angiographic lesions in patients in tertile 2 and tertile 3 compared with tertile 1. Multivariable logistic regression model 1 included adjustment for age and body mass index (BMI). Multivariable logistic regression model 2 included adjustment for age, BMI, past history of hypertension and diabetes mellitus, familial history of ischemic heart disease, and smoking.
PCSK9, proprotein convertase subtilisin/kexin type 9; OR, odds ratio; CI, confidence interval.
aP value of tertile 3 (highest PCSK9) compared with tertile 1 (lowest PCSK9).
Table 4
Associations between serum PCSK9 concentrations and scores indicating the severity of coronary artery occlusion
![dmj-42-207-i004](/upload/SynapseXML/2004dmj/thumb/dmj-42-207-i004.jpg)
βstandard | P value | |
---|---|---|
SYNTAX score | ||
Unadjusted | 0.191 | 0.035 |
Model 1 | 0.196 | 0.041 |
Model 2 | 0.204 | 0.037 |
GRACE score | ||
Unadjusted | 0.266 | 0.003 |
Model 1 | 0.203 | 0.009 |
Model 2 | 0.214 | 0.007 |
Multivariable regression model 1 included adjustment for age and body mass index (BMI). Multivariable regression model 2 included adjustment for age, BMI, past history of hypertension and diabetes mellitus, familial history of ischemic heart disease, and smoking.
PCSK9, proprotein convertase subtilisin/kexin type 9; SYNTAX, SYNergy between percutaneous coronary intervention with (paclitaxel-eluting) TAXUS stent and cardiac surgery; GRACE, Global Registry of Acute Coronary Events.